Integrating Clinical and Genomic Risk to Guide Abiraterone Use in High-Risk Prostate Cancer - Krishnan Patel
Krishnan Patel presents a pooled analysis of RTOG trials 9202, 9413, 9902, and 0521, examining whether the Decipher® genomic classifier improves risk stratification for abiraterone intensification decisions in high-risk localized prostate cancer.
